D35 Endotoxin-Free (A-class TLR9 Ligand )

Product#: FNK-CN-65001
$1,056.83
Availability:
Ships in 1-2 Weeks

D35 Endotoxin-Free (A-class TLR9 Ligand )

Cat. No. FNK-CN-65001
Size 10mg
Storage -20°C 

Description

TLR9 Ligand (CpG-ODN) for pDCs and B-cells D35 and K3
CpG Oligodeoxy nucleotide (CpG-ODN), which contains CpG-motif, has a function to stimulate immune system through Toll-like receptor 9 (TLR9) and promote maturation and activation of antigen presenting cells (APCs). This mimics immuno-stimulation activity of bacterial DNA.

D35 is categorized in "A-class" TLR9 ligand. D35 strongly induces production of type I Interferon (IFN) by activating pDCs and PBMCs, but it shows lower activity to B-cells.

K3 is categorized in "B-class" TLR9 ligand. K3 induces activation of TLR9-dependent NF-kB signal by stimulating B-cells, but it shows lower activity for inducing IFN-alpha.

Common features of both D35 and K3

  • Strong and Specific immune stimulation for human and mouse immune cells.
  • High purity
  • Endotoxin-free (<0.5 EU/mg)
  • Can be used for in vivo study (*These items are for research use only)
  • Bulk amount and GMP-grade product is available.
Features of D35
  • A-class TLR9 ligand
  • Induce production of type I Interfron (IFN) by activating pDCs and PBMCs,
  • Lower activity to B-cells.
Features of K3
  • B-class TLR9 ligand
  • Induce production of Interleukin 6 (IL-6) from human PBMC
  • Induce activation of TLR9-dependent NF-kB signal by stimulating B-cells
  • Lower activity for inducing IFN-alpha.
Example Data
CN-65001_fig1.jpg 
Fig. 1 Cytokine induction from human PBMCs
Human PBMC (1 x 10^6 cells) were stimulated with each CpG (1 μM) for 24 hours.IFN-alpha and IL-6 in culture supernatant were measured by ELISA. Bar graph shows average +/- SEM.

CN-65001_fig2.jpg
Fig. 2 Cytokine induction from mouse FL-DCs
FL-DCs (2 x 10^6 cells) derived from mouse bone marrow were differentiated by FLT3L and stimulated by each CpG (1 μM) for 24 hours. IFN-alpha and IL-6 in culture supernatant were measured by ELISA. Bar graph shows average +/- SEM.

*Data are provided by courtesy of Dr. Ken Ishii and Dr. Taiki Aoshi (Laboratory of Adjuvant Innovation, National Institutes of Biomedical Innovation, Health and Nutrition), as the result of joint study.

L0g0_GDI.png

Satisfaction
Quality Rating
Value Rating
Style Rating
X